RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Investigator
- Michael R Bubb
- Status
- Accepting Candidates
- Ages
- 18 Years - 65 Years
- Sexes
- All
Accepted insurances
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.
See all insurancesMy locations
Active clinical trials
This is an open-label, multi-center, non-randomized, Phase 1/2 study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with active lupus nephritis (LN) or primary membranous nephropathy…
- Investigator
- Michael R Bubb
- Status
- Accepting Candidates
- Ages
- 18 Years - 70 Years
- Sexes
- All
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity.
- Investigator
- Michael R Bubb
- Status
- Accepting Candidates
- Ages
- 16 Years - N/A
- Sexes
- All
My research
Top areas of exploration
- Actins , 38 publications
- Microfilament Proteins , 19 publications
- Amino Acid Sequence , 18 publications
- Protein Binding , 14 publications
Research activity
My areas of focus
Stories and news
UF Center for Regenerative Medicine recruiting for trial on potential therapy for autoimmune disorders
August 2, 2022
The University of Florida Center for Regenerative Medicine today announced the launch of a clinical trial to test safe dosages of umbilical cord-derived stem…
Division of Rheumatology and Clinical Immunology, +4 more
